177 related articles for article (PubMed ID: 25132683)
1. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N
Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N
Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222
[TBL] [Abstract][Full Text] [Related]
3. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
Takagi S; Oh-hara T; Sato S; Gong B; Takami M; Fujita N
Int J Cancer; 2014 Jun; 134(11):2605-14. PubMed ID: 24222607
[TBL] [Abstract][Full Text] [Related]
4. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N
PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201
[TBL] [Abstract][Full Text] [Related]
5. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.
Kunita A; Kashima TG; Morishita Y; Fukayama M; Kato Y; Tsuruo T; Fujita N
Am J Pathol; 2007 Apr; 170(4):1337-47. PubMed ID: 17392172
[TBL] [Abstract][Full Text] [Related]
6. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis.
Nakazawa Y; Sato S; Naito M; Kato Y; Mishima K; Arai H; Tsuruo T; Fujita N
Blood; 2008 Sep; 112(5):1730-9. PubMed ID: 18541721
[TBL] [Abstract][Full Text] [Related]
7. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
8. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis.
Fujita N; Takagi S
J Biochem; 2012 Nov; 152(5):407-13. PubMed ID: 22992842
[TBL] [Abstract][Full Text] [Related]
9. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.
Kato Y; Fujita N; Kunita A; Sato S; Kaneko M; Osawa M; Tsuruo T
J Biol Chem; 2003 Dec; 278(51):51599-605. PubMed ID: 14522983
[TBL] [Abstract][Full Text] [Related]
12. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells.
Kaneko M; Kato Y; Kunita A; Fujita N; Tsuruo T; Osawa M
J Biol Chem; 2004 Sep; 279(37):38838-43. PubMed ID: 15231832
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor podoplanin: from discovery to drug development.
Takemoto A; Miyata K; Fujita N
Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
[TBL] [Abstract][Full Text] [Related]
16. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Kato Y; Kaneko MK
Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
18. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor.
Kaneko MK; Kato Y; Kitano T; Osawa M
Gene; 2006 Aug; 378():52-7. PubMed ID: 16766141
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma.
Kato Y; Kaneko M; Sata M; Fujita N; Tsuruo T; Osawa M
Tumour Biol; 2005; 26(4):195-200. PubMed ID: 16006773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
